Skip to content

Study · Observational study · n = 206 · 2026

5 results

Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes.

Skandov MD, Christensen KM, Dalin DA, Unkerskov J, Brønden A, Lund M, Christensen MB, Karstoft K

Diabetes, obesity & metabolism8 Jul 2026Cited by 1 (Europe PMC)

PMID42420793 (opens in a new tab)PMCIDPMC13538733 (opens in a new tab)DOI10.1111/dom.71092 (opens in a new tab)PepBankPUB-42420793
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults with overweight or obesity treated in primary care in Denmark, relative mean body weight change after 12 months of semaglutide was -13.6% in those who had not discontinued treatment.

    In plain wordsIn adults in Danish primary care who stayed on semaglutide, body weight fell by about 13.6% after 12 months.

    Peptide
    Semaglutide
    Outcome
    DecreaseRelative mean body weight change at 12 months
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Relative mean body weight change
    −13.6%
    12 months

    Source sentences

    Summary
    Relative mean body weight change after 12 months was -13.6 (95% CI -15.0 to -12.2)%.
    2 context sentences
    Summary · context
    The primary outcome was the relative mean change in body weight from baseline to 12-months follow-up in individuals who had not discontinued treatment and who had a baseline and a follow-up weight.
    Summary · context
    This retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark.
  2. 02HumanObservational studyOther

    In adults prescribed semaglutide for weight management in Danish primary care, 38% had permanently discontinued semaglutide 12 months after treatment initiation.

    In plain wordsIn Danish primary care, 38% of adults had permanently stopped semaglutide for weight loss after 12 months.

    Peptide
    Semaglutide
    Outcome
    Not applicablePermanent discontinuation at 12 months
    Study

    n = 206

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Permanent discontinuation
    38%
    12 months

    Source sentences

    Summary
    Twelve months after treatment initiation, 38% (n = 78)
    1 context sentence
    Summary · context
    This retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark.
  3. 03HumanObservational studyOther

    In adults prescribed semaglutide for weight management in Danish primary care, 15% had temporarily discontinued semaglutide at 12 months.

    In plain wordsIn Danish primary care, 15% of adults had paused semaglutide for weight loss at 12 months.

    Peptide
    Semaglutide
    Outcome
    Not applicableTemporary discontinuation (pause) at 12 months
    Study

    n = 206

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Temporary discontinuation
    15%
    12 months

    Source sentences

    Summary
    whilst 15% (n = 30) had temporarily discontinued (paused) semaglutide.
    1 context sentence
    Summary · context
    This retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark.
  4. 04HumanObservational studyOther

    In adults prescribed semaglutide for weight management in Danish primary care, approximately 48% remained on treatment at 12 months.

    In plain wordsIn Danish primary care, about 48% of adults were still taking semaglutide for weight loss at 12 months.

    Peptide
    Semaglutide
    Outcome
    Not applicableRemained on treatment at 12 months
    Study

    n = 206

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Remained on treatment
    48%
    12 months

    Source sentences

    Summary
    Approximately 48% (n = 98) remained on treatment.
    1 context sentence
    Summary · context
    This retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark.
  5. 05HumanObservational studyOther

    Among adults who remained on semaglutide at 12 months, 40% took 1.0 mg/week or less, 30% took 1.7 mg/week and 30% took 2.4 mg/week.

    In plain wordsAmong adults still on semaglutide at 12 months, 40% used 1.0 mg a week or less, and 30% each used 1.7 mg or 2.4 mg.

    Peptide
    Semaglutide
    Outcome
    Not applicableWeekly dose distribution among those on treatment at 12 months
    Study

    n = 98

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Share on <=1.0 mg/week
    40%
    remained on treatment
    Share on 1.7 mg/week
    30%
    remained on treatment
    Share on 2.4 mg/week
    30%
    remained on treatment

    Source sentences

    Summary
    Amongst these, 40% were treated with ≤ 1.0 mg/week, 30% with 1.7 mg/week and 30% with 2.4 mg/week.
    1 context sentence
    Summary · context
    This retrospective, observational study included adults prescribed semaglutide for weight management between December 2022 and May 2024 in one general practise in Denmark.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.